Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107991 | 0.93 | LMNA (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| Aniline SCHEMBL27715502 | 0.92 | LMNA (0.56) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9573674 | 0.91 | LMNA (0.55) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL8264787 | 0.89 | ALDH1A1 (0.59) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL7622043 | 0.87 | LMNA (0.51) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL25693348 | 0.86 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13876814 | 0.86 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL27271917 | 0.86 | ALDH1A1 (0.51) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL6648982 | 0.86 | HTT (0.62) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL733157 | 0.86 | LMNA (0.71) | LMNASMN1; SMN2HTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651203-A | Preparation method of intermediate of DP-IV inhibitor augustine | 河南医学高等专科学校 | 2019-04-19 | — | — | CN | claimed |
| CN-104379578-B | Carbamate compounds and its preparation and application | 阿比德治疗公司 | 2017-06-09 | — | — | CN | claimed |
| CN-102171202-A | Pyridine and pyrimidine based compounds as WNT signaling pathway inhibitors for the treatment of cancer | CANCER REC TECH LTD | 2011-08-31 | — | — | CN | claimed |
| JP-2007511607-A | — | — | 2007-05-10 | — | — | JP | claimed |
| CN-1284777-C | 5-membered heterocycles, preparation and use thereof as medicine | SOD CONSEILS RECH APPLIC (FR) | 2006-11-15 | — | — | CN | claimed |
| EP-1706129-A1 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005049064-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-06-02 | — | — | WO | claimed |
| CN-1535267-A | 5-membered heterocycles, preparation and use thereof as medicine | ��ѧ�о���Ӧ����ѯ��˾ | 2004-10-06 | — | — | CN | claimed |
| CN-1447789-A | Compounds for treating alzheimer's disease | ELAN PHARM INC (US) | 2003-10-08 | — | — | CN | claimed |
| CN-1430603-A | Novel bicyclic compounds | ASAHI CHEMICAL IND (JP) | 2003-07-16 | — | — | CN | claimed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0468231-B1 | Guanidins | HOFFMANN LA ROCHE (CH) | 1994-09-21 | — | — | EP | claimed |
| WO-2025107969-A1 | QUANTUM DOT INK, QUANTUM-DOT-LAYER PATTERNING METHOD, AND QUANTUM-DOT LIGHT-EMITTING DEVICE | 京东方科技集团股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-113166075-B | Pyridazinone herbicides and pyridazinone intermediates for preparing the same | FMC公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2023215306-A1 | PROCESSES FOR MAKING NAG-25, A CARBOHYDRATE TARGETING MOIETY, AND ITS INTERMEDIATES | AMGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-09-28 | — | — | US | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0311521-B1 | CEPHALOSPORIN DERIVATIVES WITH IMPROVED PHARMACOKINETICS, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATE | ELF SANOFI (FR) | 1992-04-08 | — | — | EP | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
| EP-0311521-A1 | Cephalosporin derivatives with improved pharmacokinetics, process for their preparation, pharmaceutical compositions containing them and intermediate | ELF SANOFI (FR) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | LMNA 792/4885SMN1; SMN2 117/4885HTT 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.